Shanghai Junshi Biosciences (HKG:1877, SHA:688180) will conduct clinical trials on JS212 injection after receiving approval from China's National Medical Products Administration, according to a Hong Kong Stock Exchange disclosure on Thursday.
The drug will be tested as a treatment for advanced malignant solid tumors in conditions such as lung cancer, breast cancer, and head and neck cancer, the pharmaceutical company said.
Junshi Bio's Hong Kong shares dropped over 4% and Shanghai shares fell less than 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.